Browse All

Current Filters

CLEAR FILTER x

TITLE

Ofatumumab Treatment Up to 8 Years Shows a Favorable and Consistent Safety Profile in People Living With Relapsing Multiple Sclerosis

Cortical Hypometabolism and Limbic/Paralimbic Hypermetabolic Activity in Multiple Sclerosis: A [F-18]FDG-PET Study